Notice: This company has been marked as potentially delisted and may not be actively trading.

Deciphera Pharmaceuticals (DCPH) Stock Forecast & Price Target

Get the Latest News and Ratings for DCPH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Deciphera Pharmaceuticals and its competitors.

DCPH Analyst Ratings Over Time

Type	Current Forecast 10/1/23 to 9/30/24	1 Month Ago 9/1/23 to 8/31/24	3 Months Ago 7/3/23 to 7/2/24	1 Year Ago 10/1/22 to 10/1/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$24.17	$24.17	$24.17	$22.71
Forecasted Upside	-5.54% Downside	-5.54% Downside	-5.54% Downside	78.57% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Trump’s weapon lurks in abandoned America (Ad)

Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…

Go here now to watch my new documentary

DCPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DCPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Deciphera Pharmaceuticals Stock vs. The Competition

Type	Deciphera Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.30	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	-5.54% Downside	818.78% Upside	6.17% Upside
News Sentiment Rating	Neutral News See Recent DCPH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/30/2024	Guggenheim 3 of 5 stars		Reiterated Rating	Buy ➝ Neutral
4/30/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Perform
4/30/2024	Barclays 3 of 5 stars		Upgrade	Underweight ➝ Equal Weight	$9.00 ➝ $26.00	+2.85%
4/29/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/29/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$26.00 ➝ $25.60	+1.55%
4/29/2024	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$25.60	+1.55%
3/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$14.00 ➝ $16.00	+2.24%
2/7/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$22.00 ➝ $23.00	+64.05%
10/31/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $30.00	+151.47%
10/30/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Overweight	$18.00 ➝ $23.00	+82.54%
2/7/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$28.00 ➝ $30.00	+79.53%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$25.00 ➝ $30.00	+66.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:15 AM ET.

DCPH Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Deciphera Pharmaceuticals is $24.17, with a high forecast of $30.00 and a low forecast of $16.00.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DCPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
: According to analysts, Deciphera Pharmaceuticals's stock has a predicted downside of -5.54% based on their 12-month stock forecasts.
: Analysts like Deciphera Pharmaceuticals less than other "medical" companies. The consensus rating for Deciphera Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DCPH compares to other companies.